GH-Axis Trifecta

Goal · Endogenous growth-hormone pulse amplification research.

Ipamorelin (selective ghrelin agonist) + CJC-1295 No DAC (GHRH(1-29) analog) + tesamorelin (FDA-approved GHRH(1-44) analog) engage all three upstream regulators of pituitary GH release. The pair Ipamorelin / CJC-1295 amplifies pulse via dual-pathway activation; tesamorelin adds the FDA-validated GHRH(1-44) mechanism that drives the longest documented pulse profile. No published research evaluates this combination as a unit.

COMPONENTS

No. 009HP 140

IPA / CJC-1295

Ghrelin-receptor + GHRH(1-29) dual pulse

No. 008HP 150

TESAMORELIN

GHRH(1-44) FDA-validated long pulse

CYCLE FRAMING

8 weeks community-reported · 4 weeks off · cycle as needed

RESEARCH NOTE

Combining multiple GH-axis agonists is not supported by published research. This is a research reference framing, not a recommendation.

SOURCED FROM PEPPU LABS

Each component is available individually as research-grade material at Peppu Studio · ≥99% purity · per-batch CoA. For laboratory research use only. No human dose is recommended.